Patients sought for new NHS trial for brain cancer after man sees tumour vanish
People diagnosed with deadly glioblastoma will receive immunotherapy with the drug ipilimumab before undergoing standard treatment, when their immune system is at its strongest.
The trial, from University College London Hospital's National Hospital for Neurology and Neurosurgery, follows a previous one on the same drug which closed because of lack of recruitment.
One patient from that trial, Ben Trotman, is still showing no signs of glioblastoma following the treatment – well over two years since he got the drug in a world first. Most people with glioblastoma die within 12-18 months.
Mr Trotman was diagnosed with glioblastoma in October 2022, when he was 40.
Now aged 43 and two years and eight months on from having the treatment, his scans are clear and there are no signs of tumour.
Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial and treated Mr Trotman, said: 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans.
'We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay – and it has so far, which we are delighted to see.'
Mr Trotman got married to Emily two months after the immunotherapy treatment and in April, his daughter Mabel was born.
Mrs Trotman said: 'Getting this diagnosis was the most traumatic experience. We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live.
'Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.'
Mr Trotman went on to have the current standard treatment of radiotherapy and chemotherapy. He has quarterly scans, which continue to be clear.
Mr Trotman said: 'We obviously don't know what the future holds but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope.
'We are focused on rebuilding the life we thought we had lost and enjoying being parents.'
Dame Siobhain McDonagh MP led a fundraising campaign to raise more than £1 million to cover the costs of the new trial.
Her sister, Baroness McDonagh, died from glioblastoma in 2023.
Dame Siobhain said: 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma.
'Changing this was Margaret's final campaign and one that I have continued in her memory.
'I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.'
Dr Paul Mulholland said: 'When I met Margaret she said to me 'what can I do to support you to cure this disease?'.
'I am incredibly grateful to her and to Siobhain whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis.
'The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy.
'We're taking everything we have learned from previous trials into this new study and we are already planning follow-on trials.
'My aim is to find a cure for glioblastoma.'
The National Brain Appeal is currently funding two posts in support of Dr Mulholland's research.
Treatment will take place at the NIHR UCLH's Clinical Research Facility and at the National Hospital for Neurology and Neurosurgery.
Patients interested in the new Win-Glio trial should discuss it with their consultant.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Leader Live
11 minutes ago
- Leader Live
Officials urge those who left school without lifesaving vaccine to get protected
It comes amid warnings that more than 418,000 children have left school with no protection against human papillomavirus (HPV) in the last three years. The HPV vaccine is offered to boys and girls when they are in Year 8 and is key to wiping out cervical cancer in the UK. Around 13 high-risk types of HPV are known to cause 99.7% of cervical cancers. The jab also protects against genital warts and head and neck cancers, such as those in the mouth or throat. Now, GP practices in England will invite 16 to 25-year-olds to have the vaccine if records show they did not have it in school. According to NHS England, more than 418,000 children left school without having the jab in the last three years, with concerns there are many more people aged 16 to 25 who are not protected. Dr Amanda Doyle, national director of primary care and community services, said: 'This vaccine is hugely important in our fight to eradicate cervical cancer but it isn't just for girls and women – it's also vital for boys and men to get vaccinated to protect themselves against cancers of the mouth, throat or genitals, while preventing spreading the HPV infection to sexual partners who could then develop cervical cancer. 'Too many lives are lost to cervical cancer so the hard work of NHS staff across the country in vaccinating and screening as many people as possible will help us to meet our ambition of wiping out this disease. 'Encouraging progress has been made recently in increasing uptake but we know there is much more to do. 'So if you're eligible for a HPV vaccination or are the parent of a child who is eligible, but didn't get the vaccine at school when they had the chance, I would urge you to come forward when your GP contacts you. 'Only a single dose is required and it could save you or your child's life.' Data shows that in the 2023/24 academic year, some 76.7% of girls and 71.2% of boys aged 14 to 15 were vaccinated against HPV by Year 10. Uptake in Year 8 increased to 72.9% among girls and 67.7% among boys, from 71.3% and 65.2% respectively a year earlier. The health service will aim to boost uptake among girls to 90% as part of plans to eliminate cervical cancer by 2040. It will also aim to increase the number of women attending cervical cancer screening appointments. Public health minister Ashley Dalton said the vaccine 'is our most powerful tool in our fight to eliminate cervical cancer by 2040' but said there is a 'long way to go'. 'Thousands of young people are still unvaccinated and vulnerable to this disease – which is so easily prevented,' she added. Last month, the UK Health Security Agency (UKHSA) warned young women in some parts of England are at greater risk of cervical cancer because not enough children are getting the jab. Analysis by the agency showed inequalities in vaccine uptake in some regions – by Year 10, HPV coverage in girls was lowest in London (64.9%) and highest in the South East (82.7%). Among boys, it was also lowest in London (58.9%) and highest in the South East (77.3%). Meanwhile, at local authority level, Year 10 vaccination levels in girls ranged from 38.7% (Lambeth in London) to 97.6% (Northumberland). Among boys, it ranged from 28.2% (Lambeth in London) to 92.2% (West Berkshire). Dr Sharif Ismail, consultant epidemiologist at UKHSA, said: 'We know that uptake of the HPV vaccination in young people has fallen significantly since the pandemic, leaving many, many thousands across the country at greater risk of HPV-related cancers. 'This is a real concern as each HPV vaccine, now just a single dose offered in schools, gives a young person good protection against the devastating impact of these cancers, which includes cervical, genital, mouth and throat cancers. 'This new catch-up campaign is a really important opportunity for us to make sure that no teenage girl or boy, young woman or man is denied that protection.'
Rhyl Journal
42 minutes ago
- Rhyl Journal
Officials urge those who left school without lifesaving vaccine to get protected
It comes amid warnings that more than 418,000 children have left school with no protection against human papillomavirus (HPV) in the last three years. The HPV vaccine is offered to boys and girls when they are in Year 8 and is key to wiping out cervical cancer in the UK. Around 13 high-risk types of HPV are known to cause 99.7% of cervical cancers. The jab also protects against genital warts and head and neck cancers, such as those in the mouth or throat. Now, GP practices in England will invite 16 to 25-year-olds to have the vaccine if records show they did not have it in school. According to NHS England, more than 418,000 children left school without having the jab in the last three years, with concerns there are many more people aged 16 to 25 who are not protected. Dr Amanda Doyle, national director of primary care and community services, said: 'This vaccine is hugely important in our fight to eradicate cervical cancer but it isn't just for girls and women – it's also vital for boys and men to get vaccinated to protect themselves against cancers of the mouth, throat or genitals, while preventing spreading the HPV infection to sexual partners who could then develop cervical cancer. 'Too many lives are lost to cervical cancer so the hard work of NHS staff across the country in vaccinating and screening as many people as possible will help us to meet our ambition of wiping out this disease. 'Encouraging progress has been made recently in increasing uptake but we know there is much more to do. 'So if you're eligible for a HPV vaccination or are the parent of a child who is eligible, but didn't get the vaccine at school when they had the chance, I would urge you to come forward when your GP contacts you. 'Only a single dose is required and it could save you or your child's life.' Data shows that in the 2023/24 academic year, some 76.7% of girls and 71.2% of boys aged 14 to 15 were vaccinated against HPV by Year 10. Uptake in Year 8 increased to 72.9% among girls and 67.7% among boys, from 71.3% and 65.2% respectively a year earlier. The health service will aim to boost uptake among girls to 90% as part of plans to eliminate cervical cancer by 2040. It will also aim to increase the number of women attending cervical cancer screening appointments. Public health minister Ashley Dalton said the vaccine 'is our most powerful tool in our fight to eliminate cervical cancer by 2040' but said there is a 'long way to go'. 'Thousands of young people are still unvaccinated and vulnerable to this disease – which is so easily prevented,' she added. Last month, the UK Health Security Agency (UKHSA) warned young women in some parts of England are at greater risk of cervical cancer because not enough children are getting the jab. Analysis by the agency showed inequalities in vaccine uptake in some regions – by Year 10, HPV coverage in girls was lowest in London (64.9%) and highest in the South East (82.7%). Among boys, it was also lowest in London (58.9%) and highest in the South East (77.3%). Meanwhile, at local authority level, Year 10 vaccination levels in girls ranged from 38.7% (Lambeth in London) to 97.6% (Northumberland). Among boys, it ranged from 28.2% (Lambeth in London) to 92.2% (West Berkshire). Dr Sharif Ismail, consultant epidemiologist at UKHSA, said: 'We know that uptake of the HPV vaccination in young people has fallen significantly since the pandemic, leaving many, many thousands across the country at greater risk of HPV-related cancers. 'This is a real concern as each HPV vaccine, now just a single dose offered in schools, gives a young person good protection against the devastating impact of these cancers, which includes cervical, genital, mouth and throat cancers. 'This new catch-up campaign is a really important opportunity for us to make sure that no teenage girl or boy, young woman or man is denied that protection.'
The Sun
an hour ago
- The Sun
I've been CURED of the deadliest form of brain cancer after being told I had months to live – I'm still here years later
A DAD given months to live after being diagnosed with the deadliest form of brain cancer saw his disease vanish - and his scans are still clear years later. Most people with glioblastoma, an aggressive and fast growing type of brain tumour, don't live past 12 to 18 months. 6 6 The Wanted's Tom Parker died from the disease in March 2022. Ben Trotman was diagnosed with glioblastoma in October 2022 at the age of 40, and brought his wedding forward after doctors said he'd likely live less than a year. But he was cleared of cancer after being given a new drug called ipilimumab, as part of a breakthrough trial. Well over two years later, Ben continues to show no signs of glioblastoma and his scans remain clear. The now 43-year-old became a dad during that time is "focused on rebuilding the life he thought he had lost". Now, the NHS has launched a new immunotherapy trial to treat the deadly brain cancer is seeking patients to take part in it. The study - set up in memory of Baroness Margaret McDonagh, who died of the disease - will recruit 16 people over an 18-month period. People diagnosed with glioblastoma will receive ipilimumab with immunotherapy, a type of cancer treatment that uses the immune system combat cancer cells. They'll then undergo current standard treatment - which includes radiotherapy, chemotherapy and surgery - while their immune system is at its strongest. The trial, ran by University College London Hospital's National Hospital for Neurology and Neurosurgery, follows a previous one for the same drug which closed due to lack of recruitment. Man, 64, plays guitar while having a brain tumour Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial and treated Ben said: "It is very unusual to have a clear scan with glioblastoma, especially when [Ben] didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans. "We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay - and it has so far, which we are delighted to see." Ben got married to Emily two months after the immunotherapy treatment and in April, his daughter Mabel was born. Emily said: "Getting this diagnosis was the most traumatic experience. 6 6 "We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live. "Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation." Ben went on to have the current standard treatment of radiotherapy and chemotherapy. He has quarterly scans, which continue to be clear. What are the symptoms of glioblastoma and how soon do they show? Glioblastomas are the most common brain tumour in adults, while also being very aggressive and deadly. Brain Tumour Research says tumours increase pressure in the skull, causing headaches. Symptoms to look for are: Headaches Loss of appetite Nausea and vomiting Loss of balance Mood swings Problems speaking Problems with memory or concentration Seizures Impaired vision The symptoms can initially be quite non-specific, meaning they could be mistaken for lots of other conditions- even stress or a hangover. The brain controls so many different functions that symptoms can vary greatly depending on where in the brain the tumour is. Glioblastomas are very fast growing. Once found, experts can see them double within seven weeks. But, according to Dr Stephen Bagley, assistant professor of medicine at Penn Medicine, the first spark of glioblastoma in the brain remains something of a mystery to medical experts. One study concluded that a glioblastoma starts growing 330 days on average - almost a year - before a diagnosis. Another found that there are changes in immune function up to five years before a diagnosis, with markers in blood samples - but symptoms only occur three months prior. The dad said: "We obviously don't know what the future holds but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope. "We are focused on rebuilding the life we thought we had lost and enjoying being parents." Dame Siobhain McDonagh MP led a fundraising campaign to raise more than £1 million to cover the costs of the new trial. 6 6 Her sister, Baroness McDonagh, died from glioblastoma in 2023. Dame Siobhain said: "My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma. "Changing this was Margaret's final campaign and one that I have continued in her memory. "I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial." Dr Mulholland said: "When I met Margaret she said to me 'what can I do to support you to cure this disease?'. "I am incredibly grateful to her and to Siobhain whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis. "The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy. "We're taking everything we have learned from previous trials into this new study and we are already planning follow-on trials. "My aim is to find a cure for glioblastoma." The National Brain Appeal is currently funding two posts in support of Dr Mulholland's research. Treatment will take place at the NIHR UCLH's Clinical Research Facility and at the National Hospital for Neurology and Neurosurgery. Patients interested in the new Win-Glio trial should discuss it with their consultant.
